Biotechnologies to tackle the challenge of neoantigen identification.

Biotechnologies to tackle the challenge of neoantigen identification.
Curr Opin Biotechnol. 2020 Jan 08;65:52-59
Authors: Arnaud M, Duchamp M, Bobisse S, Renaud P, Coukos G, Harari A
Abstract
Among immune correlates of clinical responses, tumor-specific neoantigens took the spotlight as relevant targets for cancer immunotherapy. The implementation of pipelines for personalized cancer therapy remains challenging due to the privacy, that is patient-specificity, of neoantigens and the low-frequency of neoantigen-specific T cells in blood and tumor samples. To overcome these obstacles, recent developments in the field of biotechnology have allowed the multiplexed identification of neoepitope-specific T cells. This review addresses the pros and cons of conventional neoantigen screening methodologies and highlights the current as well as the prospective biotechnological opportunities in the field.
PMID: 31927304 [PubMed - as supplied by publisher]

Source: Current Opinion in Biotechnology - January 7, 2020 Category: Biotechnology Authors: Arnaud M, Duchamp M, Bobisse S, Renaud P, Coukos G, Harari A Tags: Curr Opin Biotechnol Source Type: research